

1 **Original antigenic sin responses to heterologous *Betacoronavirus* spike proteins**  
2 **are observed in mice following intramuscular administration, but are not apparent**  
3 **in children following SARS-CoV-2 infection**

4

5 **Authors:** Stacey A. Lapp,<sup>1,2</sup> Venkata Viswanadh Edara,<sup>1,2,3</sup> Austin Lu,<sup>1,2</sup> Lilin Lai,<sup>1,2,3</sup> Laila  
6 Hussaini,<sup>1,2</sup> Ann Chahroudi,<sup>1,2</sup> Larry J. Anderson,<sup>1,2</sup> Mehul S. Suthar,<sup>1,2,3</sup> Evan J. Anderson,<sup>1,2,4</sup>  
7 Christina A. Rostad<sup>1,2\*</sup>

8 **Affiliations:**

- 9 1) Department of Pediatrics, Emory University School of Medicine, Atlanta, GA USA  
10 2) Center for Childhood Infections and Vaccines, Children's Healthcare of Atlanta and Emory  
11 University School of Medicine, Atlanta, GA USA  
12 3) Yerkes Primate Center, Emory University, Atlanta, GA USA  
13 4) Department of Medicine, Emory University School of Medicine, Atlanta, GA USA

14 \*Corresponding Author: [Christina.rostad@emory.edu](mailto:Christina.rostad@emory.edu) (CAR)

15 **Short Title:** Original antigenic sin responses to coronavirus spike proteins

16 **Author Contributions:** SAL and CAR contributed to study conceptualization, funding acquisition,  
17 resources, data curation, investigation, and original drafting of the manuscript. AL, LH, and EJA  
18 contributed to data curation. LJA, EJA, AC contributed to study conceptualization, funding  
19 acquisition and resources. MSS, VE, and LL contributed to study investigation by performing  
20 neutralizing antibody experiments. All authors contributed to writing, review, and editing of the  
21 manuscript.

22

23

## 24 **Abstract**

25

26 **Background:** The effects of pre-existing endemic human coronavirus (HCoV) immunity on  
27 SARS-CoV-2 serologic and clinical responses are incompletely understood.

28 **Objectives:** We sought to determine the effects of prior exposure to HCoV *Betacoronavirus*  
29 HKU1 spike protein on serologic responses to SARS-CoV-2 spike protein after intramuscular  
30 administration in mice. We also sought to understand the baseline seroprevalence of HKU1  
31 spike antibodies in healthy children and to measure their correlation with SARS-CoV-2 binding  
32 and neutralizing antibodies in children hospitalized with acute coronavirus disease 2019  
33 (COVID-19) or multisystem inflammatory syndrome (MIS-C).

34 **Methods:** Groups of 5 mice were injected intramuscularly with two doses of alum-adjuvanted  
35 HKU1 spike followed by SARS-CoV-2 spike; or the reciprocal regimen of SARS-Cov-2 spike  
36 followed by HKU1 spike. Sera collected 21 days following each injection was analyzed for IgG  
37 antibodies to HKU1 spike, SARS-CoV-2 spike, and SARS-CoV-2 neutralization. Sera from  
38 children hospitalized with acute COVID-19, MIS-C or healthy controls (n=14 per group) were  
39 analyzed for these same antibodies.

40 **Results:** Mice primed with SARS-CoV-2 spike and boosted with HKU1 spike developed high  
41 titers of SARS-CoV-2 binding and neutralizing antibodies; however, mice primed with HKU1  
42 spike and boosted with SARS-CoV-2 spike were unable to mount neutralizing antibodies to  
43 SARS-CoV-2. HKU1 spike antibodies were detected in all children with acute COVID-19, MIS-  
44 C, and healthy controls. Although children with MIS-C had significantly higher HKU1 spike titers  
45 than healthy children (GMT 37239 vs. 7551,  $P=0.012$ ), these titers correlated *positively* with  
46 both SARS-CoV-2 binding ( $r=0.7577$ ,  $P<0.001$ ) and neutralizing ( $r=0.6201$ ,  $P=0.001$ ) antibodies.

47 **Conclusions:** Prior murine exposure to HKU1 spike protein completely impeded the  
48 development of neutralizing antibodies to SARS-CoV-2, consistent with original antigenic sin. In

49 contrast, the presence of HKU1 spike IgG antibodies in children with acute COVID-19 or MIS-C  
50 was not associated with diminished neutralizing antibody responses to SARS-CoV-2.

51

## 52 Introduction

53

54 As the coronavirus disease 2019 (COVID-19) pandemic continues and the first  
55 vaccinations are administered, our understanding of the immune responses to SARS-CoV-2  
56 continues to evolve. A prevailing question has been what role pre-existing immunity to endemic  
57 human coronaviruses (HCoVs) plays in the serologic responses to SARS-CoV-2. The  
58 *Betacoronaviruses*, HKU1 and OC43, and *Alphacoronaviruses*, 229E and NL63, cause seasonal  
59 respiratory illnesses in both adults and children worldwide. Seroprevalence data indicate that  
60 infection with HCoVs occurs during early childhood (1), and the majority of adults are seropositive  
61 with antibody titers that wane over time (2, 3). Cross-reactive antibodies are elicited within genera,  
62 but less so between *Alphacoronaviruses* and *Betacoronaviruses* (4). Cross-reactive antibodies  
63 are predominantly directed against non-neutralizing antigens, including the S2 subunit of the spike  
64 protein and nucleocapsid proteins. Because children have more frequent exposures to HCoVs,  
65 some have hypothesized that pre-existing cross-reactive immunity to HCoVs may in part explain  
66 the reduced COVID-19 disease severity observed in children (5-7).

67 Although SARS-CoV-2 is a *Betacoronavirus*, it shares only 33% amino acid identity with  
68 the HCoV *Betacoronaviruses* within the spike protein, which is the predominant immunogen and  
69 neutralizing antigen of coronaviruses. Thus, although some pre-pandemic sera do have SARS-  
70 CoV-2 spike-reactive antibodies, these antibodies are poorly neutralizing (8). The widespread  
71 seroprevalence of SARS-CoV-2 binding, non-neutralizing antibodies has led to concern that pre-  
72 existing immunity from prior HCoV exposures may contribute to aberrant serologic responses to  
73 the antigenically similar SARS-CoV-2, as in original antigenic sin (OAS). OAS refers to the  
74 preferential induction of antibodies directed against an original, priming antigen rather than a

75 structurally similar boosting antigen. The mechanism of OAS is thought to be attributable to the  
76 initial development and differentiation of memory B cells directed against the original antigen of  
77 exposure. Upon secondary exposure to a structurally similar antigen, these memory B cells  
78 undergo clonal expansion to preferentially produce antibodies directed against the original priming  
79 antigen. The phenomenon of OAS has been well described with several other viruses including  
80 dengue and influenza, and has led to concerns about its impact on disease severity and vaccine  
81 development (9).

82 In this study, our objectives included determining if prior exposure to HKU1 spike protein  
83 in a mouse model impacted serologic responses to SARS-CoV-2 upon spike protein challenge.  
84 We further sought to determine the baseline seroprevalence of HKU1 spike antibodies in healthy  
85 children and to assess if the presence or titer of HKU1 antibody affected the response to SARS-  
86 CoV-2 binding and neutralizing antibodies in children hospitalized with acute COVID-19 or  
87 multisystem inflammatory syndrome (MIS-C).

88

## 89 **Experimental Results**


90

### 91 **Murine Results**

92 Two groups of five BALB/c mice were injected intramuscularly (IM) with 10 µg each of  
93 alum-adjuvanted full-length spike protein antigens according to the schedule shown in Figure 1.  
94 One group received a prime (d0) and boost (d21) with SARS-CoV-2 full-length spike protein,  
95 followed by a prime (d42) and boost (d63) with HCoV HKU1 full-length spike protein. The second  
96 group received a reciprocal immunization regimen of a prime and boost with HKU1 spike followed  
97 by SARS-CoV-2 spike prime and boost. Submandibular bleed samples were collected at 3 weeks  
98 following each injection, and a terminal bleed was performed 3 weeks following the last injection.

99

100



101  
102  
103  
104  
105  
106  
107  
108  
109

**Figure 1. Schematic of intramuscular spike protein administrations in groups of five BALB/c mice.** Group 1 received prime and boost with SARS-CoV-2 spike, followed by prime and boost with HKU1 spike. Group 2 received a reciprocal administration regimen, with prime and boost with HKU1 spike, followed by prime and boost by HKU1 spike. D, days post-administration; S, spike; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2. \*These mice were immunized with nucleocapsid protein 21 and 42 days prior to utilization for this study.

110  
111  
112  
113  
114  
115  
116  
117  
118  
119  
120

We measured IgG antibody titers to SARS-CoV-2 spike and HKU1 spike antigens in the two groups of mice by ELISA. We also measured the neutralizing antibody titers of these plasma samples using a Focus Reduction Neutralization Test (FRNT) with an infectious clone of SARS-CoV-2 virus (Wuhan strain, A.1 based on PANGO lineage) as previously described (10, 11) (Fig 2). As expected, the SARS-CoV-2 spike-primed mice developed SARS-CoV-2 spike IgG antibodies that significantly increased in titer after the first injection (1914 vs. 85,  $P=0.012$ ) and peaked at 21 days after the SARS-CoV-2 spike boost (139316 vs 85,  $P<0.001$ , Fig 2A). The SARS-CoV-2 spike IgG antibody titers did not further increase after subsequent administration of HKU1 spike. The HKU1 spike-primed mice also generated cross-reactive anti-SARS-CoV-2 spike IgG antibodies that reached statistical significance on day 21 post-HKU1 spike boost (2594 vs. 85,  $P=0.018$ , Fig 2B). Subsequent injection with SARS-CoV-2 spike incrementally boosted SARS-

121 CoV-2 spike IgG titers, which increased significantly after the second boost (51523 vs. 2594,  
122  $P=0.031$ ).


123 Analogously, SARS-CoV-2 spike-primed mice developed cross-reactive HKU1 spike  
124 binding IgG antibodies, but these did not significantly increase above baseline following either the  
125 first (137 vs. 85,  $P=0.990$ ) or second injection (2851 vs. 85,  $P=0.116$ , Fig 2C). Subsequent  
126 immunization with HKU1 spike protein increased the HKU1 spike IgG titers significantly over  
127 baseline (10351 vs. 85,  $P=0.038$ ) which were maintained after HKU1 spike boost (39719 vs.  
128 10351,  $P=0.750$ , Fig 2C). As expected, the HKU1 spike-primed mice generated HKU1 spike-  
129 binding IgG titers that increased significantly after the initial HKU1 injection (1197 vs. 85,  $P=0.001$ )  
130 and peaked following HKU1 boost (106167 vs. 85,  $P<0.001$ , Fig 2D). Subsequent injection with  
131 SARS-CoV-2 spike protein did not further increase HKU1 spike IgG titers.

132 We then performed SARS-CoV-2 neutralizing FRNT antibody assays with these samples  
133 using an infectious clone of SARS-CoV-2. Only the SARS-CoV-2 spike primed mice generated  
134 neutralizing antibodies to SARS-CoV-2 (Fig 2E). Neutralizing titers significantly increased  
135 compared to baseline after the boost immunization of SARS-CoV-2 spike (180 vs. 31,  $P=0.006$ )  
136 and further increased following the second HKU1 spike boost (520 vs. 180,  $P=0.050$ ),  
137 demonstrating that HKU1 spike boosted neutralizing antibodies to SARS-CoV-2. In contrast, the  
138 HKU1 spike/SARS-CoV-2 prime-boosted mice did not generate neutralizing antibodies to SARS-  
139 CoV-2 following any administration of antigen (Fig 2F). Thus, recent prior exposure to the endemic  
140 HKU1 coronavirus adjuvanted spike protein completely impeded the development of SARS-CoV-  
141 2 neutralizing antibodies in mice upon SARS-CoV-2 spike protein administration. These data  
142 indicate that the SARS-CoV-2 spike boost immunization predominantly boosted cross-reactive  
143 antibodies to the original priming (HKU1) antigen at shared, non-neutralizing epitopes.

144

145

146



147  
148  
149  
150  
151  
152  
153  
154  
155  
156  
157

**Figure 2. Priming mice with HKU1 spike protein prior to boosting with SARS-CoV-2 spike protein completely impeded the development of SARS-CoV-2 neutralizing antibodies.** SARS-CoV-2 (A,B) and HKU1 (C,D) full-length spike IgG binding and SARS-CoV-2 neutralizing (E, F) antibodies in mice are shown as log(end-point titer). Group 1 was primed with two doses of alum-adjuvanted SARS-CoV-2 spike and boosted with two doses of alum-adjuvanted HKU1 spike (A, C, E). Group 2 received the reciprocal regimen of HKU1 spike prime and SARS-CoV-2 spike boost (B, D, F). \* $P < 0.05$ ; \*\* $P < 0.01$ ; \*\*\* $P < 0.005$ ; \*\*\*\* $P < 0.001$ .

## 158 Results in Children

159 Because our mouse data suggested that prior exposure to endemic coronaviruses may  
160 blunt serologic responses to SARS-CoV-2 by the phenomenon of original antigenic sin, we next  
161 measured the baseline seroprevalence of IgG antibodies to both SARS-CoV-2 and HKU1 spike  
162 proteins in healthy children (n=14) using pre-pandemic sera. The healthy, asymptomatic children

163 were recruited from the community to participate in a phlebotomy study between 2016-2018, and  
 164 they were comprised of 10 females (71%), median age 8 years (IQR 2.3-11.8 years), 8 (57%)  
 165 Black, 4 (29%) White, 2 (14%) other race, and 14 (100%) non-Hispanic ethnicity. The geometric  
 166 mean antibody titers from healthy children were then compared to children hospitalized at  
 167 Children’s Healthcare of Atlanta with acute COVID-19 (n=14) or MIS-C (n=14) (Table 1, Figure 3)  
 168 using one-way analysis of variance (ANOVA) of log-transformed titers.

169  
 170 **Table 1. Clinical and demographic characteristics of patient cohort of children hospitalized**  
 171 **with acute COVID-19 or MIS-C at Children’s Healthcare of Atlanta.**

	COVID-19 (n=14)		MIS-C (n=14)		P-value
		n		n	
<b>Age, years, mean (SD)</b>	10.9 (7.6)	14	9.1 (3.9)	14	0.436
<b>Gender, female, n (%)</b>	8 (57%)	14	7 (50%)	14	0.379
<b>Race, n (%)</b>					<b>0.006</b>
Black	4 (29%)	14	12 (86%)	14	
White	9 (64%)	14	1 (7%)	14	
Declined	1 (7%)	14		14	
<b>Ethnicity, n (%)</b>					0.065
Hispanic	5 (36%)	14	1 (7%)	14	
Non-Hispanic	9 (64%)	14	13 (93%)	14	
<b>Disease Severity, n (%)</b>					<b>0.002</b>
Mild/moderate	10 (71%)	14	2 (14%)	14	
Severe	4 (29%)	14	12 (86%)	14	
<b>Labs, mean (SD)</b>					
WBC max, x10 <sup>3</sup> cells/μL	11.7 (5.8)	13	11.9 (6.2)	14	0.932
ALC min, cells/μL	2262.9 (1703.4)	13	1055.1 (673.1)	14	<b>0.021</b>
Platelets min, x10 <sup>3</sup> cells/μL	262.2 (106.0)	13	153.8 (84.4)	14	<b>0.007</b>
ESR max, mm/hr	34.9 (36.2)	7	53.6 (22.8)	10	0.209
Sodium min, mmol/L	137.3 (2.1)	13	133.1 (4.6)	14	<b>0.006</b>
Creatinine max, mg/dL	0.6 (0.2)	13	1.1 (0.7)	14	<b>0.02</b>
ALT max, U/L	148.5 (396.6)	13	71.9 (48.5)	14	0.479
BNP max, pg/mL	21.5 (16.1)	5	1774.1 (1260.3)	13	<b>0.008</b>
Troponin max, ng/mL	0.015 (0.0)	4	1.2 (1.7)	10	0.193
Ferritin max, ng/mL	217.5 (134.2)	10	1385.4 (1278.5)	14	<b>0.009</b>
CRP max, mg/dL	6.8 (7.5)	12	19.5 (10.4)	14	<b>0.002</b>
<b>Imaging</b>					
CXR, n (%)					




Infiltrates	3 (33%)	9	10 (83%)	12	<b>0.02</b>
Pleural effusions	3 (33%)	9	9 (75%)	12	0.056
Echocardiogram, n (%)					
Depressed function	0 (0%)	4	7 (50%)	14	0.07
Coronary artery dilation	0 (0%)	4	2 (14%)	14	0.423
Treatment, n (%)					
Remdesivir	4 (29%)	14	1 (7%)	14	0.139
IVIG	0 (0%)	14	13 (93%)	14	<b>&lt;0.001</b>
Steroids	5 (36%)	14	12 (86%)	14	<b>0.007</b>
Antiplatelet	0 (0%)	14	13 (93%)	14	<b>&lt;0.001</b>
<b>Outcomes</b>					
Days of hospitalization, mean (SD)	6.1 (7.8)	14	9.4 (6)	14	0.221
ICU admission, n (%)	5 (36%)	14	12 (86%)	14	<b>0.007</b>
Days of ICU, mean (SD)	2.6 (5.6)	14	5.8 (5)	14	0.123
Low-flow O <sub>2</sub> , n (%)	5 (36%)	14	11 (79%)	14	<b>0.022</b>
Mechanical ventilation, n (%)	0 (0%)	14	2 (14%)	14	0.142
Vasopressors, n (%)	0 (0%)	14	10 (71%)	14	<b>&lt;0.001</b>
Death, n (%)	0 (0%)	14	0 (0%)	14	---

172 Max, maximum value obtained during the hospitalization; Min, minimum value obtained during the hospitalization; WBC,  
 173 white blood cell count; ALC, absolute lymphocyte count; ESR, erythrocyte sedimentation rate; ALT, alanine  
 174 aminotransferase; BNP, brain natriuretic peptide; CRP, C-reactive protein; CXR, chest radiograph; IVIG, intravenous  
 175 immunoglobulin; ICU, intensive care unit; O<sub>2</sub>, oxygen.  
 176

177 As expected, we found significantly higher SARS-CoV-2 spike IgG titers in children with  
 178 acute COVID-19 (7727 vs. 1019,  $P<0.001$ ) and MIS-C (46989 vs. 1019,  $P<0.001$ ) compared to  
 179 healthy controls (Fig 3A). Moreover, children with MIS-C had significantly higher SARS-CoV-2  
 180 spike IgG titers compared to those with acute COVID-19 (Fig 3A,  $P<0.001$ ), as we have previously  
 181 shown (12). All healthy controls had detectable antibodies to HKU1 spike with a wide range of  
 182 titers (GMT 7551, 95% CI 3317 to 17190, Fig 3B). We found no difference in HKU1 spike IgG  
 183 titers between healthy controls and children with COVID-19 (7551 vs. 9376,  $P=0.917$ ), but children  
 184 with MIS-C had significantly higher HKU1 spike IgG titers compared with healthy children (37239  
 185 vs. 7551,  $P=0.012$ ) and those with acute COVID-19 (37239 vs. 9376,  $P=0.043$ , respectively).

186 We then tested the ability of plasma from the groups of children to neutralize an infectious  
 187 clone of the SARS-CoV-2 virus using the FRNT assay. Plasma from healthy controls failed to  
 188 neutralize SARS-CoV-2. In contrast, plasma from children with acute COVID-19 (33 vs. 10 (lower


189 LOD),  $P=0.002$ ) and MIS-C (94 vs. 10,  $P<0.001$ ) had significantly higher SARS-CoV-2  
190 neutralization titers compared to healthy children (Fig 3C). Children with MIS-C also had  
191 significantly higher neutralizing titers compared to children with acute COVID-19 ( $P=0.005$ ). Thus,  
192 although HKU1 spike antibodies were prevalent in healthy children with acute COVID-19 and  
193 MIS-C were able to mount strong neutralizing antibody responses to SARS-CoV-2.



194  
195 **Figure 3. HKU1 antibodies are prevalent in healthy children and children with acute COVID-**  
196 **19 and MIS-C.** SARS-CoV-2 (A) and HKU1 (B) spike IgG antibody titers and FRNT neutralization  
197 titers (C) in healthy pediatric controls compared to children hospitalized with acute COVID-19 and  
198 MIS-C. \* $P<0.05$ ; \*\* $P<0.01$ ; \*\*\* $P<0.005$ ; \*\*\*\* $P<0.001$ .  
199

200 We next performed multiple linear regression analyses and determined the Spearman  
201 correlations between the serologic assays among children with acute COVID-19 and MIS-C. We  
202 found that HKU1 spike IgG binding antibodies correlated strongly with SARS-CoV-2 spike binding  
203 antibody titers in children with acute COVID-19 and MIS-C ( $r=0.7577$ ,  $P<0.001$ ) (Fig 4A). HKU1  
204 spike IgG antibodies also correlated positively with SARS-CoV-2 neutralizing antibodies  
205 ( $r=0.6201$ ,  $P=0.001$ ) (Fig 4B), although the correlation was not as strong as that of SARS-CoV-2  
206 spike IgG with neutralizing antibodies ( $r=0.7599$ ,  $P<0.001$ ) (Fig 4C). Thus, our clinical data  
207 demonstrated that HKU1 spike antibodies are prevalent in healthy children, that they are higher  
208 in titer in children with MIS-C, and that they correlate with both SARS-CoV-2 spike binding and  
209 neutralizing antibodies in acute COVID-19 and MIS-C.

210



211  
212 **Figure 4. HKU1 spike IgG antibodies correlated positively with both SAR-CoV-2 spike IgG**  
213 **and SARS-CoV-2 neutralizing antibodies in children with acute COVID-19 and MIS-C.** Linear  
214 regression analyses compared the log-transformed antibody titers of (A) SARS-CoV-2 spike IgG  
215 vs. HKU1 spike IgG; (B) HKU1 spike IgG vs. SARS-CoV-2 neutralization titers; and (C) SARS-  
216 CoV-2 spike IgG vs. SARS-CoV-2 neutralization titers among children with acute COVID-19 or  
217 MIS-C. Spearman's correlation coefficients ( $r$ ) and P-values are shown.  
218

## 219 Discussion

220  
221 In this study, we found that priming mice with an endemic coronavirus HKU1 spike protein  
222 impeded the development of neutralizing antibodies to SARS-CoV-2 upon challenge with SARS-  
223 CoV-2 spike, consistent with original antigenic sin (OAS). Boosting mice intramuscularly with the  
224 heterologous coronavirus adjuvanted spike protein appeared to preferentially boost antibodies  
225 directed at the priming spike protein at shared, non-neutralizing epitopes. The phenomenon of  
226 OAS has been described in humans and animals with influenza (13, 14), dengue (15, 16), and  
227 human rhinovirus (17). The pathophysiology of OAS is thought to be attributable to sequential  
228 exposure to similar, but non-identical antigens which preferentially elicits antibodies to the original  
229 antigen due to immunologic memory B cells (9). Our data provides evidence that OAS plays a  
230 role in the murine serologic response to the spike protein of coronaviruses upon sequential  
231 exposure.

232 In contrast, analysis of clinical specimens from children with COVID-19 and MIS-C  
233 suggests that the serologic responses to SARS-CoV-2 in children may be amoral. Healthy

234 pediatric controls had a wide range of pre-existing, binding antibody titers to HCoV HKU1 spike,  
235 reflecting a high baseline seroprevalence in children. Nevertheless, children with acute COVID-  
236 19 and MIS-C were able to effectively mount a neutralizing antibody response that correlated  
237 positively with both SARS-CoV-2 and HKU1 spike IgG antibodies. Thus, there was no direct  
238 evidence of OAS observed in our pediatric cohort. This discrepancy with the experimental model  
239 of adjuvanted antigen administration in mice may be in part because the human immune system  
240 is capable of overcoming OAS, dependent upon factors relative to the original and subsequent  
241 antigen exposures.

242 To date, the literature describing the role of pre-existing HCoV immunity on SARS-CoV-2  
243 serologic and clinical responses has been conflicting. Ng, et. al found that SARS-CoV-2 spike  
244 antibodies were prevalent in pre-pandemic sera, and that these were primarily IgG antibodies  
245 directed against the S2 subunit (8). Interestingly, these cross-reactive antibodies possessed some  
246 neutralizing activity against SARS-CoV-2 pseudotyped viruses. This data conflicts with the pre-  
247 print findings of Anderson, et. al which demonstrated that endemic HCoV antibodies are boosted  
248 by SARS-CoV-2 infection, but are not associated with neutralization or protection against SARS-  
249 CoV-2 infections or hospitalizations (18). However, Sagar, et. al found that although recent  
250 endemic coronavirus infections did not impact susceptibility to SARS-CoV-2 infections or  
251 hospitalizations, they were associated with significant improvements in patient outcomes  
252 including mortality (19). Thus, the role of pre-existing antibodies to endemic coronaviruses in  
253 SARS-CoV-2 immune responses and outcomes is incompletely understood.

254 Limitations of this study include the small number of mice in each group, and the limited  
255 number of available clinical samples. Importantly, we also lacked pre- and post-COVID-19 sera  
256 in a single patient cohort to definitively answer the question of the effects of pre-existing HCoV  
257 antibodies on SARS-CoV-2 acquisition and clinical outcomes. Population-based studies may  
258 provide greater insights into subtler effects of pre-existing HCoV cross-reactive immunity on  
259 SARS-CoV-2 infection. We only analyzed serologic immunity to one endemic coronavirus (HKU1

260 in the *Betacoronavirus* genus), and differences could exist among *Alphacoronaviruses* (229E and  
261 NL63) or with the other endemic *Betacoronavirus* (OC43). While HKU1 infection is less prevalent  
262 than NL63 and OC43, it shares more homology in the spike protein with SARS-CoV-2 compared  
263 to the other HCoVs (20, 21), so we chose to evaluate it for this reason in these experiments. Pre-  
264 existing immunity to other SARS-CoV-2 antigens such as the nucleocapsid protein may contribute  
265 to clinical response, but we did not evaluate these antibodies in this study. The converse question  
266 of whether SARS-CoV-2 antibodies could blunt serologic responses to endemic coronaviruses or  
267 to emerging SARS-CoV-2 variants remains to be determined.

## 268 **Conclusions**

269  
270 Prior exposure to endemic coronaviruses may blunt serologic responses to SARS-CoV-2  
271 in mice by impeding the development of neutralizing antibodies, consistent with original antigenic  
272 sin. In comparison, our data in children suggest an amoral immune response. Future studies are  
273 needed to determine the effects of pre-existing immunity to endemic coronaviruses on clinical  
274 outcomes in children with acute COVID-19 and MIS-C.

275

## 276 **Experimental Methods**

277

### 278 **Mouse experiments**

279 Six to 8-week-old female BALB/c mice were obtained from Jackson Laboratory (Bar  
280 Harbor, ME) and housed in pathogen-free conditions. All animal experiments were conducted  
281 according to approved protocols by the Emory University Institutional Animal Care and Use  
282 Committee (PROTO202000026).

283 One group of five Balb/c mice was primed and boosted at 21 days IM with 10 µg SARS-  
284 CoV-2 nucleocapsid protein (SinoBiological, 40588-V08B) in 50 µl with alum (Alhydrogel adjuvant

285 2%, Invivogen). The purpose of this was to generate polyclonal antiserum to the nucleocapsid  
286 protein early during the COVID-19 pandemic, which was not a part of the present study. These  
287 mice were immunized 3 weeks later analogously with 10 µg alum-adjuvanted HCoV-HKU1 S1+S2  
288 ECD-His (SinoBiological, 40606-V08B) IM, followed by an identical boost 21 days later. Three  
289 weeks later the same mice were immunized with 10 µg alum-adjuvanted SARS-CoV-2 S1+S2  
290 ECD-His (SinoBiological, 40589-V08B1) IM, followed by a final boost 21 days later. Plasma was  
291 collected by submandibular bleeding on day 21 following each administration. A terminal bleed  
292 via cardiac puncture was conducted 21 days after the final boost.

293 A second group of five mice was immunized with 10 µg alum-adjuvanted SARS-CoV-2  
294 S1+S2 ECD-His followed by a boost 21 days later. The mice were immunized 3 weeks later with  
295 10 µg alum-adjuvanted HCoV-HKU1 S1+S2 ECD-His, followed by a boost 21 days later. Blood  
296 was collected as described above. Serum samples from each group were pooled and all serologic  
297 analyses were performed on pooled samples in duplicate.

## 298 **Human subjects**

299 Children and adolescents, 0 to 21 years of age, hospitalized at Children's Healthcare of  
300 Atlanta (CHOA) with confirmed or suspected COVID-19 or MIS-C were enrolled into an IRB-  
301 approved specimen collection protocol (Emory University IRB protocols STUDY00022371 and  
302 STUDY00000723) following written or verbal informed consent and assent as appropriate for age  
303 as previously described (12). The Emory University IRB approved obtaining verbal consent and  
304 assent under specific circumstances, including to limit staff exposure to COVID-19. If verbal  
305 consent and assent were obtained, this was documented on the approved ICF form by the staff  
306 member who obtained consent. Children were classified as having MIS-C if they met the Centers  
307 for Disease Control and Prevention case definition (22). They were classified as having acute  
308 COVID-19 if they were hospitalized with symptomatic disease and had SARS-CoV-2 detected by  
309 nasopharyngeal (NP) real-time polymerase chain reaction (RT-PCR). Prospective blood samples  
310 were collected from patients at the time of enrollment, and residual samples leftover from clinical

311 labs were also obtained from the clinical laboratory. Plasma from healthy pediatric controls was  
312 collected through a separate IRB-approved protocol (STUDY0008846) following written informed  
313 consent and assent, as appropriate for age. Partial non-HKU1 serologic data from a subset of  
314 these children (4 with acute COVID-19 and 7 with MIS-C) were included in a prior publication (12).  
315 Of the 126 planned analyses (3 groups, 14 patients per group, 3 types of serologic assays), there  
316 was insufficient volume to complete 5 assays. Data is available in the supporting information.

### 317 **Serology**

318 Recombinant SARS-CoV-2 S1+S2 ECD-His (SinoBiological, 40589-V08B1) and HCoV-  
319 HKU1 S1+S2 ECD-His (SinoBiological, 40606-V08B) were coated onto Nunc MaxiSorp plates at  
320 a concentration of 0.5 µg/mL in 100 µL phosphate-buffered saline (PBS) at 4°C overnight. Plates  
321 were blocked for two hours at room temperature in PBS/1% BSA/0.05% Tween-20 (ELISA buffer).  
322 Serum or plasma samples were heated to 56°C for 30 min, aliquoted, and stored at -20°C before  
323 use. Samples were serially diluted 1:3 in dilution buffer (PBS/1% BSA/0.05% Tween-20) starting  
324 at a dilution of 1:100. Coated plates were washed 4 times with 300 µl PBS/0.05% Tween-20  
325 before adding 100 µL of each dilution and incubated for 90 minutes at room temperature. Plates  
326 were washed 4 times with PBS/0.05% Tween-20, and 100 µL of horseradish peroxidase-  
327 conjugated anti-Fc IgG antibody (Jackson ImmunoResearch Laboratories, 109-035-098), diluted  
328 1:5,000 in ELISA buffer, was added and incubated for 60 minutes at room temperature. Plates  
329 were washed 4 times with PBS/0.05% Tween-20, followed by one additional wash with 1X PBS.  
330 Development was performed using 0.4 mg/mL o-phenylenediamine substrate (Sigma) in 0.05 M  
331 phosphate-citrate buffer pH 5.0, supplemented with 0.012% hydrogen peroxide before use.  
332 Reactions were incubated for 5 minutes then stopped with 1 M HCl and absorbance was  
333 measured at 490 nm.

### 334 **Focus Reduction Neutralization Assays**

335 FRNT assays were performed as previously described (11). Briefly, samples were diluted at 3-fold  
336 in 8 serial dilutions using DMEM (VWR, #45000-304) in duplicates with an initial dilution of 1:10 in a total

337 volume of 60  $\mu$ l. Serially diluted samples were incubated with an equal volume of an infectious clone of  
338 SARS-CoV-2 (Wuhan strain, A.1 from PANGO lineage) (100-200 foci per well) at 37°C for 1 hour in a round-  
339 bottomed 96-well culture plate. The antibody-virus mixture was then added to Vero cells and incubated at  
340 37°C for 1 hour. Post-incubation, the antibody-virus mixture was removed and 100  $\mu$ l of prewarmed 0.85%  
341 methylcellulose (Sigma-Aldrich, #M0512-250G) overlay was added to each well. Plates were incubated at  
342 37°C for 24 hours. After 24 hours, methylcellulose overlay was removed, and cells were washed three times  
343 with PBS. Cells were then fixed with 2% paraformaldehyde in PBS (Electron Microscopy Sciences) for 30  
344 minutes. Following fixation, plates were washed twice with PBS and 100  $\mu$ l of permeabilization buffer (0.1%  
345 BSA [VWR, #0332], Saponin [Sigma, 47036-250G-F] in PBS), was added to the fixed Vero cells for 20  
346 minutes. Cells were incubated with an anti-SARS-CoV spike primary antibody directly conjugated to biotin  
347 (CR3022-biotin) for 1 hour at room temperature. Next, the cells were washed three times in PBS and avidin-  
348 HRP was added for 1 hour at room temperature followed by three washes in PBS. Foci were visualized  
349 using TrueBlue HRP substrate (KPL, # 5510-0050) and imaged on an ELISPOT reader (CTL). **Statistical**

## 350 **Analysis**

351 Statistical comparisons were made with GraphPad Prism (v9.0). Antibody geometric mean  
352 titers (GMTs) of replicates were determined and log-transformed titers were compared using one-  
353 way analysis of variance (ANOVA). Linear regression was performed on log-transformed antibody  
354 titers, and the Spearman's correlation coefficients ( $r$ ) were calculated.  $P$  values  $\leq 0.05$  were  
355 considered statistically significant.

356

## 357 **Figure Legends**

358

359 **Figure 1. Schematic of intramuscular spike protein administrations in groups of five**  
360 **BALB/c mice.** Group 1 received prime and boost with SARS-CoV-2 spike, followed by prime and  
361 boost with HKU1 spike. Group 2 received a reciprocal administration regimen, with prime and  
362 boost with HKU1 spike, followed by prime and boost by HKU1 spike. D, days post-administration;



363 S, spike; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2. \*These mice were  
364 immunized with nucleocapsid protein 21 and 42 days prior to utilization for this study.

365 **Figure 2. Priming mice with HKU1 spike protein prior to boosting with SARS-CoV-2 spike**  
366 **protein completely impeded the development of SARS-CoV-2 neutralizing antibodies.**

367 SARS-CoV-2 (A,B) and HKU1 (C,D) full-length spike IgG binding and SARS-CoV-2 neutralizing  
368 (E, F) antibodies in mice are shown as log(end-point titer). Group 1 was primed with two doses of  
369 alum-adjuvanted SARS-CoV-2 spike and boosted with two doses of alum-adjuvanted HKU1 spike  
370 (A, C, E). Group 2 received the reciprocal regimen of HKU1 spike prime and SARS-CoV-2 spike  
371 boost (B, D, F). \* $P < 0.05$ ; \*\* $P < 0.01$ ; \*\*\* $P < 0.005$ ; \*\*\*\* $P < 0.001$ .

372 **Figure 3. HKU1 antibodies are prevalent in healthy children and children with acute COVID-**  
373 **19 and MIS-C.** SARS-CoV-2 (A) and HKU1 (B) spike IgG antibody titers and FRNT neutralization  
374 titers (C) in healthy pediatric controls compared to children hospitalized with acute COVID-19 and  
375 MIS-C. Each dot represents a unique patient, and data represent the geometric mean titers of  
376 \* $P < 0.05$ ; \*\* $P < 0.01$ ; \*\*\* $P < 0.005$ ; \*\*\*\* $P < 0.001$ .

377 **Figure 4. HKU1 spike IgG antibodies correlated positively with both SAR-CoV-2 spike IgG**  
378 **and SARS-CoV-2 neutralizing antibodies in children with acute COVID-19 and MIS-C.** Linear  
379 regression analyses compared the log-transformed antibody titers of (A) SARS-CoV-2 spike IgG  
380 vs. HKU1 spike IgG; (B) HKU1 spike IgG vs. SARS-CoV-2 neutralization titers; and (C) SARS-  
381 CoV-2 spike IgG vs. SARS-CoV-2 neutralization titers among children with acute COVID-19 or  
382 MIS-C. Spearman's correlation coefficients ( $r$ ) are shown.

## 383 **Acknowledgements**

384  
385 We thank clinical research coordinators Beena Desai, Kerry Dibernardo, Felicia Glover, Vikash  
386 Patel, Maureen Richardson, Amber Samuel, and clinical research nurses Lisa Macoy and Kathy  
387 Stephens for their assistance enrolling patients and collecting specimens. We thank Nadine

388 Roupshael and the Hope Clinic laboratory, Theda Gibson, Hui-Mien Hsiao, Wensheng Li, and the  
389 Emory Vaccine Research Center laboratory for their assistance processing specimens. We thank  
390 the Children's Healthcare of Atlanta research laboratory for their assistance in collecting residual  
391 specimens. We thank the professional staff of Emory Division of Animal Resources for their  
392 assistance with animal studies. Lastly, we thank the clinical study participants and their families  
393 for generously donating their time and samples to further our understanding of COVID-19 and  
394 MIS-C in children.

## 395 **Conflicts of Interest**

396  
397 E.J.A. has received personal fees from AbbVie, Pfizer, and Sanofi Pasteur for consulting, and his  
398 institution receives funds to conduct clinical research unrelated to this manuscript from  
399 MedImmune, Regeneron, PaxVax, Pfizer, GSK, Merck, Novavax, Sanofi-Pasteur, Janssen, and  
400 Micron. He also serves on a safety monitoring board for Sanofi-Pasteur and Kentucky  
401 BioProcessing, Inc.

402 C.A.R.'s institution has received funds to conduct clinical research unrelated to this manuscript  
403 from BioFire Inc, GSK, MedImmune, Micron, Janssen, Merck, Moderna, Novavax, PaxVax, Pfizer,  
404 Regeneron, Sanofi-Pasteur. She is co-inventor of patented RSV vaccine technology unrelated to  
405 this manuscript, which has been licensed to Meissa Vaccines, Inc.

## 406 **Funding Statement**

407  
408 This work was funded by a Center for Childhood Infections and Vaccines (CCIV) pilot award from  
409 Children's Healthcare of Atlanta and Emory University School of Medicine (to C.A.R.) and a Fast  
410 Grant from Emergent Ventures at the Mercatus Center at George Mason University (to A.C.). The  
411 funders had no role in study design, data collection and analysis, decision to publish, or  
412 preparation of the manuscript.

## 413 References

414

- 415 1. Grimwood K, Lambert SB, Ware RS. Endemic Non-SARS-CoV-2 Human Coronaviruses in a  
416 Community-Based Australian Birth Cohort. *Pediatrics*. 2020;146(5).
- 417 2. Ogimi C, Englund JA, Bradford MC, Qin X, Boeckh M, Waghmare A. Characteristics and Outcomes  
418 of Coronavirus Infection in Children: The Role of Viral Factors and an Immunocompromised State. *J*  
419 *Pediatric Infect Dis Soc*. 2019;8(1):21-8.
- 420 3. Gao X, Zhou H, Wu C, Xiao Y, Ren L, Paranhos-Baccala G, et al. Antibody against nucleocapsid  
421 protein predicts susceptibility to human coronavirus infection. *J Infect*. 2015;71(5):599-602.
- 422 4. Trivedi SU, Miao C, Sanchez JE, Caidi H, Tamin A, Haynes L, et al. Development and Evaluation of  
423 a Multiplexed Immunoassay for Simultaneous Detection of Serum IgG Antibodies to Six Human  
424 Coronaviruses. *Sci Rep*. 2019;9(1):1390.
- 425 5. Hicks J, Klumpp-Thomas C, Kalish H, Shunmugavel A, Mehalko J, Denson J-P, et al. Serologic  
426 cross-reactivity of SARS-CoV-2 with endemic and seasonal Betacoronaviruses. *medRxiv*.  
427 2020:2020.06.22.20137695.
- 428 6. Huang AT, Garcia-Carreras B, Hitchings MDT, Yang B, Katzelnick LC, Rattigan SM, et al. A  
429 systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection,  
430 and association with severity. *Nature Communications*. 2020;11(1):4704.
- 431 7. Steinman JB, Lum FM, Ho PP-K, Kaminski N, Steinman L. Reduced development of COVID-19 in  
432 children reveals molecular checkpoints gating pathogenesis illuminating potential therapeutics.  
433 *Proceedings of the National Academy of Sciences*. 2020;117(40):24620.
- 434 8. Ng KW, Faulkner N, Cornish GH, Rosa A, Harvey R, Hussain S, et al. Preexisting and de novo  
435 humoral immunity to SARS-CoV-2 in humans. *Science*. 2020;370(6522):1339-43.
- 436 9. Vatti A, Monsalve DM, Pacheco Y, Chang C, Anaya JM, Gershwin ME. Original antigenic sin: A  
437 comprehensive review. *J Autoimmun*. 2017;83:12-21.
- 438 10. Suthar MS, Zimmerman MG, Kauffman RC, Mantus G, Linderman SL, Hudson WH, et al. Rapid  
439 Generation of Neutralizing Antibody Responses in COVID-19 Patients. *Cell Rep Med*. 2020;1(3):100040.
- 440 11. Vanderheiden A, Edara VV, Floyd K, Kauffman RC, Mantus G, Anderson E, et al. Development of  
441 a Rapid Focus Reduction Neutralization Test Assay for Measuring SARS-CoV-2 Neutralizing Antibodies.  
442 *Curr Protoc Immunol*. 2020;131(1):e116.
- 443 12. Rostad CA, Chahroudi A, Mantus G, Lapp SA, Teherani M, Macoy L, et al. Quantitative SARS-CoV-  
444 2 Serology in Children With Multisystem Inflammatory Syndrome (MIS-C). *Pediatrics*.  
445 2020;146(6):e2020018242.
- 446 13. Kim JH, Davis WG, Sambhara S, Jacob J. Strategies to alleviate original antigenic sin responses to  
447 influenza viruses. *Proc Natl Acad Sci U S A*. 2012;109(34):13751-6.
- 448 14. Davenport FM, Hennessy AV, Francis T, Jr. Epidemiologic and immunologic significance of age  
449 distribution of antibody to antigenic variants of influenza virus. *J Exp Med*. 1953;98(6):641-56.
- 450 15. Halstead SB, Rojanasuphot S, Sangkawibha N. Original antigenic sin in dengue. *Am J Trop Med*  
451 *Hyg*. 1983;32(1):154-6.
- 452 16. Mongkolsapaya J, Dejnirattisai W, Xu XN, Vasanawathana S, Tangthawornchaikul N, Chairunsri  
453 A, et al. Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever. *Nature*  
454 *medicine*. 2003;9(7):921-7.
- 455 17. Lee S, Nguyen MT, Currier MG, Jenkins JB, Strobert EA, Kajon AE, et al. A polyvalent inactivated  
456 rhinovirus vaccine is broadly immunogenic in rhesus macaques. *Nat Commun*. 2016;7:12838.
- 457 18. Anderson EM, Goodwin EC, Verma A, Arevalo CP, Bolton MJ, Weirick ME, et al. Seasonal human  
458 coronavirus antibodies are boosted upon SARS-CoV-2 infection but not associated with protection. *Cell*.  
459 2021.

- 460 19. Sagar M, Reifler K, Rossi M, Miller NS, Sinha P, White LF, et al. Recent endemic coronavirus  
461 infection is associated with less-severe COVID-19. *J Clin Invest.* 2021;131(1).  
462 20. Dijkman R, Jebbink MF, Gaunt E, Rossen JW, Templeton KE, Kuijpers TW, et al. The dominance of  
463 human coronavirus OC43 and NL63 infections in infants. *J Clin Virol.* 2012;53(2):135-9.  
464 21. Jaimes JA, André NM, Chappie JS, Millet JK, Whittaker GR. Phylogenetic Analysis and Structural  
465 Modeling of SARS-CoV-2 Spike Protein Reveals an Evolutionary Distinct and Proteolytically Sensitive  
466 Activation Loop. *J Mol Biol.* 2020;432(10):3309-25.  
467 22. CDC Health Alert Network. Multisystem inflammatory syndrome in children (MIS-C) associated  
468 with coronavirus disease 2019 (COVID-19) 2020 [Available from:  
469 <https://emergency.cdc.gov/han/2020/han00432.asp>.

470